Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

asc chm

  • Home
  •  
  • asc chm



  • Most Read
  • Latest Comments
  • There are no scorpions involved in this company’s latest cancer drug
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • There are no scorpions involved in this company’s latest cancer drug
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • There are no scorpions involved in this company’s latest cancer drug
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • There are no scorpions involved in this company’s latest cancer drug
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • There are no scorpions involved in this company’s latest cancer drug
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Arovella completes development for cell therapy platform, moves to large scale manufacturing
    Arovella completes development for cell therapy platform, moves to large scale manufacturing
    • News

  • Chimeric Therapeutics granted US patent for its blood cancer technology
    Chimeric Therapeutics granted US patent for its blood cancer technology
    • News

  • Chimeric’s cell therapy drug moves on to Phase 1B trial to treat malignant brain cancer
    Chimeric’s cell therapy drug moves on to Phase 1B trial to treat malignant brain cancer
    • News

  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

  • Prescient Therapeutics sures supply of cell therapeutic in the hopes of commencing clinical trials
    Prescient Therapeutics sures supply of cell therapeutic in the hopes of commencing clinical trials
    • News

  • There are no scorpions involved in this company’s latest cancer drug
    • News

    There are no scorpions involved in this company’s latest cancer drug

    Most company announcements include a one paragraph summary of the business conveniently located at the bottom of the page. Chimeric Therapeutics (ASX: CHM) however, has a one page run down of their business, a clear sign that they work with complex scientific principles and diseases.  Whilst investors might initially shy away from the wall of

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.